Abstract
Many clinical grade preparations of hGH (human growth hormone) are contaminated with hLH and hFSH. However, no evidence of a clinical effect of such contamination has been described. We report the development of antibodies to hLH in a patient treated with hGH for isolated GH deficiency.
J.C. was first investigated for short stature at 7-11/12 years and GH therapy was begun at 8-9/12 years for a diagnosis of isolated GH deficiency. On LRF (luteinizing hormone releasing factor) testing, the LH rose from 0.8 to 1.2 ng/ml (LER 960); FSH response also was normal. At 11-11/12 years the patient was still prepubertal with undetectable testosterone levels. A repeat LRF test revealed an “apparent” basal plasma LH of 25.4 ng/ml. Further studies indicated that his serum had antibodies to hLH which have persisted for over 2-1/2 years on growth hormone therapy without the development of significant GH antibodies. 125I-hLH was bound to his serum in a displacable fashion; hFSH and hTSH displaced this tracer only at doses compatible with contamination of these standards by hLH. Radioiodinated hFSH, hTSH and hLH-α were not bound; the antibody is directed against the LH-β subunit. The binding capacity of the serum and the equilibrium constant for the binding reaction are sufficiently great to be physiologically significant.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burstein, S., Conte, F., Kaplan, S. et al. 284 ANTIBODIES TO LUTEINIZING HORMONE IN A PATIENT TREATED WITH GROWTH HORMONE. Pediatr Res 12 (Suppl 4), 411 (1978). https://doi.org/10.1203/00006450-197804001-00289
Issue date:
DOI: https://doi.org/10.1203/00006450-197804001-00289
